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ver the past 2 decades,the diagnostic classifica-
tion of dementias has been continuously adapted to the
increasing knowledge derived from clinical symptomatol-
ogy,neuropathology,biochemistry,and clinicopathological
comparisons.Before,dementias were attributed primarily
to cerebral vascular insufficiency.Later,with the diagno-
sis of Alzheimer’s disease (AD) predominating,further
differentiations were categorized:frontotemporal demen-
tia (FTD),dementia with Lewy bodies (DLB),vascular
dementia (VD),prion disease,dementia with argyrophilic
grains, British dementia, and many more.This develop-
ment was driven by the results of molecular analyses of the
abnormal protein deposits in the brain of the respective
diseases in relation to the clinical syndromes.The careful
clinical and neurochemical investigation of dementias has
led to practical guidelines and improvements in current
treatment and care,eg,the use of atypical neuroleptics in
patients with DLB due to the high susceptibility to side
effects by treatment with typical antipsychotics.
More excitingly,the dissection of the molecular mecha-
nisms and species involved in the aggregation process may
allow for the development of specific therapies,which may,
in the future,contribute to the prevention and treatment
of neurodegenerative diseases.
The following diseases are characterized by the deposition
of protein aggregates,termed amyloid,derived from the
Greek amylum (starch, sugar); the term was first intro-
duced by Virchow in 1854 on the basis of color after stain-
ing with iodine, since he assumed that polysaccharides
were the major constituents of amyloid deposits in periph-
eral tissues.
1The secondary structure of amyloid deposits
both in the brain as well as in peripheral organs shows a
strong tendency towards formation of β-pleated sheets;the
tertiary structure forms high-order quasi-crystalline com-
plexes that are birefringent under polarized light (eg,when
stained with Congo red),and fibrils can be identified by
electron microscopy.
1,2 Table I lists the neurodegenerative
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Alzheimer’s disease, frontotemporal dementia, dementia
with Lewy bodies, and prion diseases are age-related neuro-
degenerative disorders associated with a progressive
decline of cognitive brain functions. Due to the increase
in prevalence rates, and the rising costs associated with
clinical and social care, treatments designed to prevent or
reverse these diseases are urgently needed. The most com-
mon major biochemical characteristic of these neurode-
generative diseases is the deposition of abnormal protein
aggregates in brain. The decryption of the mechanisms of
aggregation and associated neurotoxicity may reveal new
therapeutic targets, which will enable treatment for these
devastating conditions.  
Dialogues Clin Neurosci. 2003;5:27-33.Alzheimer’s disease
AD is the most common form of dementia. It affects
about 20 to 30 million people worldwide.
3,4 The preva-
lence increases exponentially with age between 55 to 64
years (less than 1%) ending up at over 20% in the over-
85 age-group.
5 Clinically, AD is characterized by pro-
gressive cognitive deficits such as impairment of memory
and orientation.With disease progression,noncognitive
symptoms such as delusions, agitation, changes in per-
sonality,and mood disturbances may also occur.From a
genetic point of view,AD may be subdivided into three
forms according to the observed mode of inheritance:
first,autosomal-dominant familial AD;second,familial
AD without clear mendelian inheritance (familial aggre-
gation);and third,sporadic AD without familial aggre-
gation.About 5% to 10% of all AD cases can be fully
explained by the presence of genetic factors in terms of
autosomal dominant AD. These cases are caused by
mutations in the genes encoding amyloid precursor pro-
tein (APP, located on chromosome 21), presenilin 1
(PSEN1, chromosome 14), and presenilin 2 (PSEN2,
chromosome 1).In other cases,a different familial aggre-
gation can be observed: relatives of AD patients show
increased risk of developing dementia compared with
relatives of healthy control subjects without clear auto-
somal-dominant inheritance.
6,7This type of familial aggre-
gation may be due to shared genetic or environmental
risk factors within families.Finally,the major proportion
of AD cases is,however,sporadic,which is defined as the
absence of evidence for familial aggregation.This group
is nevertheless influenced by so-called susceptibility
genes that confer a minor genetic risk associated with
allelic variations in the form of single nucleotide poly-
morphisms (SNPs).
Histopathologically, AD is characterized by two hall-
marks:the extracellular β-amyloid plaques with amyloid
β-peptides (Aβ) as major constituents,and the intracel-
lular neurofibrillary tangles (NFTs), ultrastructurally
described as paired helical filaments (PHFs), made up
predominantly by tau proteins.Aβ peptides are 38 to 42
amino acids in length and are derived by endoproteolysis
of APP by the combined activities of β-secretase (BACE)
at the amino terminal and γ-secretase that cleave at the
C-terminal,respectively,of the Aβ domain.
8Alternative
amino terminal cleavage by β-secretase (tumor necrosis
factor–α convertase [TACE]/A Disintegrin And Metallo-
proteinase [ADAM10]) within the Aβ domain results in
the generation of nonamyloidogenic fragments.Mutations
in all three genes causing familial AD—APP,PSEN1,and
PSEN2—alter the processing of APP toward the pro-
duction of more amyloidogenic Aβ species.
9
Genetic,histopathological,and other experimental find-
ings prompted the hypothesis that Aβ peptides are an
essential feature of the pathogenetic cascade causing AD:
Aβ deposits into β-amyloid plaques and causes neuronal
dysfunction,ultimately leading to neurodegeneration and
dementia.
10Aβ40 and,in particular,Aβ42 rapidly aggregate
to form oligomers,protofibrils,and fibrils
11 that can deposit
into β-amyloid plaques,induce cell death,
12 and accelerate
formation of NFTs.
13,14 The brain β-amyloid burden
increases with age and correlates with the learning capac-
ities in mutated APP-transgenic mice.
15 The functional
impact of fibrillar Aβpeptides was demonstrated by Walsh
et al
16 in a series of experiments using APP V717F Chinese
hamster ovary cells.Intracerebroventricular microinjec-
tion of conditioned medium of these cells containing
sodium dodecyl sulfate (SDS)–stable Aβ oligomers
resulted in marked reduction in long-term potentiation
(LTP) in the hippocampus,a measure of synaptic plastic-
ity.Possibly,the formation of a pore-like morphology by
Aβ protofibrils resembling cytolytic pore-forming toxins
from bacteria plays a role in Aβ-mediated neurotoxicity.
17
These experiments strongly suggest that Aβ aggregation
drives the pathology of AD.It remains to be shown which
state of the aggregation process is the most toxic: the
oligomers,protofibrils,fibrils,or the compact aggregates.
Based on the findings mentioned above, oligomers and
protofibrils are clearly suspects as central players in the
aggregation process.This hypothesis is supported by the
recent finding of Nilsberth et al
18:they discovered a path-
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Selected abbreviations and acronyms
AD Alzheimer’s disease
APP amyloid precursor protein
CJD Creutzfeldt-Jakob disease
CNS central nervous system





PHF paired helical filament
SNP single nucleotide polymorphism
VD vascular dementiaogenic APP mutation,located within the Aβsequence,that
causes early-onset AD in a Swedish family.Aβ with the
Arctic mutation formed protofibrils at a much higher rate
and in larger quantities than wild-type Aβ.Thus,rapid Aβ
protofibril formation may lead to accelerated buildup of
insoluble Aβ intracellularly and/or extracellularly, and
thereby cause early-onset AD.
Collectively, AD is caused by formation of fibrils and
aggregates of Aβ peptides,a cleavage product from APP,
which is a transmembrane type I protein with neurotrophic
function.Mutations in genes encoding for APP,presenilin
1,and presenilin 2 result in early onset of AD by increased
production of Aβ peptides.Sporadic forms of AD may be
caused by impaired clearance of Aβaggregates from brain.
Frontotemporal dementia
FTD designates a clinical syndrome characterized by
behavioral changes,including social misconduct,disinhibi-
tion,hyperorality,apathy,etc,and also memory deficits.
19-21
Usually,the behavioral symptoms outweigh the cognitive
deficits in these patients.Among the neurological features,
Parkinsonism can develop with disease progression and
may become predominant in some patients.
19 FTD was
clinically classified by consensus criteria some years ago
22,23
and was therefore supposed to be underrecognized by the
usual dementia screening procedures established in the
last decades in dementia clinics.It is estimated that FTD
accounts for up to 20% of dementia with early onset.
18The
subclassification list includes such syndromes as frontal
dementia, progressive aphasia, and semantic dementia.
The frontal type includes Pick’s disease,characterized by
circumscribed frontal or temporal atrophy,as one specific
and rare subtype.Neuropathological features of FTD are
diffuse bilateral atrophy of the frontal and anterior tem-
poral lobes and degeneration of the striatum.Histopatho-
logical findings include loss of large cortical nerve cells and
spongiform (microvacuolar) degeneration of the superfi-
cial neuropil,gliosis,and tau- or ubiquitin-positive inclu-
sion bodies.
19 The microtubule-associated tau proteins are
essential for the assembly and stabilization of micro-
tubules.
24Tau proteins are widely expressed in the central
nervous system (CNS),predominantly in axons,and to a
much lesser extent in glial cells.
25 During neurodegenera-
tive diseases,tau is redistributed to the somatodendritic
compartments. In the human brain, six isoforms of tau
ranging from 352 to 441 amino acids are produced from a
single gene mapping to 17q21 by alternative mRNA splic-
ing.
25 In the AD brain,PHF tau is abnormally phosphory-
lated.
26 Consequently,the kinases and phosphatases regu-
lating tau phosphorylation are a focus of therapeutic
research.
A portion of FTD syndromes is characterized by promi-
nent filamentous tau inclusions and neurodegeneration in
the absence of β-amyloid deposition.This tau form of FTD
was therefore grouped together with other neurodegener-
ative diseases where tau pathology was predominant and
termed “tauopathies”:sporadic corticobasal degeneration,
progressive supranuclear palsy,Pick’s disease,as well as
hereditary FTD and Parkinsonism linked to chromosome
17 (FTD-17).
25 Clinical manifestations of the tauopathies
are not restricted to the brain; they may include other
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Table I. Neurodegenerative diseases are associated with deposition of abnormal proteins in brain. BSE, bovine spongiform encephalopathy.
Disease Abnormal protein Deposition Gene Chromosome Other brain diseases with 
similar abnormal 
protein deposits
Alzheimer’s Aββ -Amyloid plaques APP Chromosome 21 Down syndrome
disease PSEN1 Chromosome 14
PSEN2 Chromosome 1
Tau Neurofibrillary tangles tau Chromosome 17
Fronto- Tau Filamentous tau deposits tau Chromosome 17 Corticobasal degeneration








Sc-positive plaques PRNP Chromosome 20 Scrapie, BSEorgan systems,eg,in Hallervorden-Spatz disease,myotonic
dystrophy,or Niemann-Pick disease type C.
Tau proteins vary among the different tauopathies in iso-
form and phosphorylation state.Since several tau muta-
tions were shown to be causative for several tauopathies
including FTD, tau abnormalities that may be mecha-
nistically involved in the pathogenesis of neurodegen-
eration were investigated. It was hypothesized that dif-
ferent tau mutations are pathogenic because they impair
tau function, promote tau fibrillization, or perturb tau
gene splicing,thereby leading to formation of biochem-
ically and structurally distinct aggregates of tau.
25
Collectively,tauopathies,including a portion of FTD,are
associated with deposition of aggregated, abnormally
phosphorylated tau proteins which normally stabilize
microtubule function in the cell.
Dementia with Lewy bodies
DLB accounts for about 20% of the dementias in the
elderly.
27This disorder has clinical and pathological fea-
tures in common with both AD and Parkinson’s disease
(PD).
19,27 Dementia is often associated with Parkinsonism,
visual hallucinations,orthostatic hypotension,and,typi-
cally,fluctuations in cognitive performance and levels of
consciousness.
19,27 Lewy bodies contain filamentous aggre-
gates and α-synuclein as major constituents
28 and deposit
in paralimbic and cortical brain areas along with neuritic
changes.
29,30 Cooccurrence of β-amyloid plaques and vas-
cular disease is frequent,whereas the presence of NFTs
is rare.
31 In contrast to FTD and in line with AD,there is
a pronounced deficit in cholinergic neurotransmission,
which makes this disease a possible indication for treat-
ment with acetylcholinesterase inhibitors.
27
α-Synuclein is abundantly expressed in presynaptic ter-
minals and probably regulates synaptic neurotransmis-
sion.
32 Mutations in the α-synuclein gene located to chro-
mosomal 4q21-23 are linked to autosomal-dominant
PD.
33,34 α-Synuclein containing Lewy pathology or α-
synuclein fibrils were also shown to be present in
Hallervorden-Spatz disease (neurodegeneration with
brain iron accumulation type 1) and multisystem atro-
phy, as well as pure autonomic failure and Lewy body
dysphagia.
32,35,36 The term multisystem atrophy summa-
rizes olivopontocerebellar atrophy, striatonigral degen-
eration,and Shy-Drager syndrome.
α-Synuclein is a naturally unfolded protein with α-helical
domains.The synuclein family consists of three members,
α-,β-,and γ-synuclein,ranging from 127 to 140 amino acids
in length.
37 In the filaments associated with PD and DLB,
the amino terminal region of α-synuclein seems to be
buried in the body of the filament,while the carboxy ter-
minal region is exposed on the filament surface.
36The con-
version of native α-synuclein to protofibrils and fibrils con-
tinues to be a matter of intense research. Factors that
promote fibril formation in vitro include high temperature,
low pH,high concentration,and oxidative conditions.
32
Together,diseases associated with Lewy bodies including
DLB are associated with abnormal neuronal aggregates
of α-synuclein,a protein associated with synaptic function.
Prion diseases
Prion diseases are caused by infectious proteins that
convert normal cellular prion protein (PrP
C) into the dis-
ease-causing scrapie (PrP
Sc) isoform.
38 In contrast to the
aforementioned neurodegenerative disorders,prion dis-
eases are transmissible and, in contrast to viruses, PrP
Sc
is encoded by a chromosomal gene,located on chromo-
some 20,termed PRPN.
The class of prion diseases summarizes such conditions as
kuru,Creutzfeldt-Jakob disease (CJD;sporadic,familial,
iatrogenic, and new variant), Gerstmann-Sträussler-
Scheinker disease, as well as fatal familial and sporadic
insomnia in humans.
38,39 In addition, prion diseases are
known in species such as sheep,cattle,mink,mule deer,
elk,cats,kudu,nyala,and oryx.
38,40The incidence of spo-
radic CJD is highest between the ages of 60 and 74,almost
5 cases per million.
37The increasing incidence of the new
variant of CJD is associated with the bovine spongiform
encephalopathy (BSE) epidemic in cattle and affects pre-
dominantly younger subjects.
41 Familial forms can be
caused by mutations in the prion gene.The clinical mani-
festations are heterogenous and include dementia,myoclo-
nia,visual disturbances,ataxia,insomnia,paraplegia,sen-
sory symptoms, and behavioral disturbances.
42 The




Sc have been found, and they occur as “florid”
plaques in the new variant CJD form, composed of a
dense core PrP
Sc amyloid plaque surrounded by vacuoles.
38
The mature PrP
C is a result of two processing steps from
the 254 amino acid PrP
C precursor protein, resulting in




Sc are identical in
amino acid sequence and posttranslational modifica-
tions, but differ in secondary and tertiary structures,
Basic research
30resulting in partial protease resistance of the latter. In
case of prion infection in humans or animals, the point
of entry is outside the nervous system.The march of pri-
ons into the CNS (“neuroinvasion”) may involve the
lymphoreticular or autonomic nervous system.
40
Together, prion diseases are caused by aggregation of
prion proteins, most likely initiated by conversion of a
physiological conformation (PrP
C) into an infectious
form (PrP
Sc), which serves as a seed that induces poly-
merization,
45 formation of fibrils,and deposition.
Neurotoxicity of protein aggregates
AD,FTD,DLB,and prion diseases share the deposition
of abnormally folded proteins as a common denominator.
All of these diseases occur predominantly sporadically
with a minor portion caused by mutations associated with
familial forms of the disease.The formation of aggregates
may be a desperate attempt to eliminate the toxicity of
misfolded proteins and their oligomeric or fibrillar states.
The pathogenetic mechanisms entail abnormal prote-
olytic cleavage,posttranslational processing,misfolding,
and reduced clearance of protein aggregates.The dissec-
tion of the kinetics of folding and deposition,the folding
intermediates,and promoting factors will be crucial for
the discovery of new therapeutic targets.
The variety of protein species that are capable of forming
β-pleated sheets, deposit into amyloid, and induce neu-
rodegeneration suggests an inherent neurotoxicity of pro-
tein aggregates.Interestingly,a range of proteins not asso-
ciated with amyloid diseases are also able to aggregate in
vitro into fibrils barely distinguishable from those found in
pathological conditions.
46-48Thus,aggregation may be viewed
as a general property of polypeptide chains that occurs in a
specific environment.Whether this process ends up in neu-
rodegeneration may depend on the selective vulnerability
determined by age-related cellular alterations,genetic back-
ground,and capacity of removal and repair mechanisms.
The neuronal cell possesses a defense machinery, eg,
chaperones,which protects against protein misfolding,a
process that occurs, like DNA replication errors, per-
manently during protein synthesis and transport.
49
Imperfectly produced proteins are degraded by a sort of
clearance pathway,such as the ubiquitin-proteasome sys-
tem.
50 Dysfunction of both the protein folding defense
system and the degrading system of defective proteins
may also contribute to the development of neurodegen-
erative diseases.
Several conclusions can be made from the dissection of
abnormal protein deposits in dementias:first,prevention
of the deposition of a specific protein, eg, β-amyloid in
AD,may be a cure for AD only,and not for the related
conditions FTD,DLB,VD,etc,since these are caused by
or associated with other protein aggregates;second,there
is cooccurrence of dementing conditions in a considerable
portion of patients,such as AD combined with VD,or AD
combined with DLB,which may require combination of
specific therapies;third,there may be an inherent toxic-
ity of protein aggregates that is independent of the spe-
cific peptide deposited.The latter may offer the search for
treatment targets that are common to a variety of neu-
rodegenerative conditions associated with protein mis-
folding,aggregation,and deposition.
The future therapy of neurodegenerative disorders may
aim to prevent the formation and deposition of abnor-
mal proteins prior to clinical manifestation of the dis-
ease.The major prerequisite for such therapeutic strate-
gies is the availability of accurate and reliable preclinical
diagnostic markers,a major challenge that is as yet unre-
solved.Clearance of deposited abnormal proteins from
brain may be another therapeutic approach in patients
who already display the neurodegenerative disease. It
remains to be shown whether such interventions would
be capable of relieving the brain of the toxic burden,
stimulate recovery of neuronal damage,and,ultimately,
result in the restoration of normal function. ❏
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Aspectos bioquímicos de las demencias
La Enfermedad de Alzheimer, la demencia fronto-
temporal, la demencia con cuerpos de Lewy y las
enfermedades por priones son trastornos neuro-
degenerativos relacionados con la edad, asociados
con una declinación progresiva de las funciones
cerebrales cognitivas. Debido al aumento en las fre-
cuencias de prevalencia y al incremento de los cos-
tos asociados a los cuidados clínicos y sociales, se
necesita en forma urgente de tratamientos diseña-
dos para prevenir o revertir estas enfermedades. La
característica bioquímica principal más común de
estas enfermedades neurodegenerativas es el
depósito de agregados de proteínas en el cerebro.
La descripción de los mecanismos de agregación y
neurotoxicidad asociados puede revelar nuevos
objetivos terapéuticos que posibilitarían trata-
mientos para estas devastadoras enfermedades. 
Aspects biochimiques des démences
La maladie d’Alzheimer, la démence frontotempo-
rale, la démence avec corps de Lewy et les maladies
à prions sont des troubles neurodégénératifs liés à
l’âge associés avec un déclin progressif des fonc-
tions cérébrales cognitives. Étant donné l’augmen-
tation des taux de prévalence et des coûts associés
aux prises en charge cliniques et sociales, il est
urgent de disposer de traitements conçus pour pré-
venir ou lutter contre ces maladies. La caractéris-
tique biochimique majeure la plus courante de ces
maladies neurodégénératives est le dépôt d’agré-
gats de protéines anormales dans le cerveau. Le
décryptage des mécanismes d’agrégation et de la
neurotoxicité associée peuvent révéler de nouvelles
cibles thérapeutiques qui permettront aux traite-
ments d’agir sur ces troubles dévastateurs. 33. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-
synuclein gene identified in families with Parkinson’s disease. Science.
1997;276:2045-2047.
34. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encod-
ing alpha-synuclein in Parkinson’s disease. Nat Genet 1998;18:106-108.
35. Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein
MJ. Alpha synuclein in neurodegenerative disorders: murderer or accom-
plice? Nat Med. 1998;4:755-757.
36. Goedert M. Alpha-Synuclein and neurodegenerative diseases. Nature.
2001;2:492-501.
37. Lavedan C, Leroy E, Torres R et al. Genomic organization and expres-
sion of the human beta-synuclein gene (SNCB). Genomics. 1998;54;173-
175. 
38. Prusiner S. Shattuck Lecture—Neurodegenerative diseases and prions.
N Engl J Med. 2001;344:1516-1526. 
39. Weissmann C, Aguzzi A. Bovine spongiform encephalopathy and early
onset variant Creutzfeldt-Jakob disease. Curr Opin Neurobiol. 1997;7:695-
700.
40. Aguzzi A, Montrasio F, Kaeser PS. Prions: health scare and biological
challenge. Nature. 2001;2:118-126.
41. Glatzel M, Rogivue C, Ghani A, Streffer JR, Amsler L, Aguzzi A. Incidence
of Creutzfeldt-Jakob disease in Switzerland. Lancet. 2002;360:139-41.
42. Brandel JP. Clinical aspects of human spongiform encephalopathies, with
the exception of iatrogenic forms. Biomed Pharmacother. 1999;53:14-18. 
43. Kretzschmar HA. Neuropathology of human prion diseases (spongiform
encephalopathies). Dev Biol Stand. 1993;80:71-90. 
44. Aguzzi A, Heppner FL. Pathogenesis of prion diseases: a progress
report. Cell Death Differ. 2000;7:889-902.
45. Jarrett JT, Lansbury PT Jr. Seeing ¨one-dimensional crystallization¨ of
amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell.
1993;73:1055-1058.
46. Chiti F, Webster P, Taddei N, et al. Designing conditions for in vitro for-
mation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A.
1999;96:3590-3594.
47. Fandrich M, Fletcher MA, Dobson CM. Amyloid fibrils from muscle myo-
globin. Nature. 2001;410:165-166.
48. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates
implies a common mechanism for protein misfolding diseases. Nature.
2002;416:507-511.
49. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative
disease. Science. 2002;296:1991-1995.
50. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem.
1998;67:425-479.
Biochemical aspects of dementias - Hock Dialogues in Clinical Neuroscience - Vol 5 . No.1 . 2003
33